Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results
Incyte Corp. (NASDAQ: INCY ) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance. The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion. "Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development," Chief Executive Officer Bill Meury said. Incyte raised its 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, up from its previous forecast of $4.77 billion to $4.94 billion. However, the updated outlook remains below the analyst consensus estimate of $5.712 billion. Incyte shares fell 1.7% to trade at $127.75 on Wednesday. These analysts made changes to their price targets on Incyte f...
Incyte Corp. (NASDAQ: INCY ) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance. 12. 46 billion.
"Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development," Chief Executive Officer Bill Meury said. 94 billion. 712 billion. 75 on Wednesday.
These analysts made changes to their price targets on Incyte following earnings announcement. HC Wainwright & Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and raised the price target from $140 to $150.
Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $134 to $139. BMO Capital analyst Evan Seigerman maintained the stock with a Market Perform and raised the price target from $112 to $130. Guggenheim maintained the stock with a Buy and boosted the price target from $136 to $150 Considering buying INCY stock? Here’s what analysts think: Photo via Shutterstock